Tauriga Sciences Inc (TAUG) 0.0072 $TAUG
Tauriga Sciences Inc. Issues Comprehensive Update to Shareholders and Reports Significant Progress on Multiple Fronts
Marketwire Canada - Wed Jun 01, 9:30AM CDT
NEW YORK, NY--(Marketwired - Jun 1, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today issued a comprehensive update to shareholders which addressed a number of important Corporate goals and milestones. The Company and its Board of Directors ("Board" strongly believe that important progress is being realized on multiple fronts.
Tauriga Sciences Inc. Completes the Successful Re-Audit of Its Fiscal Year 2014 Financial Statements and Files Its Fiscal Year 2015 Form 10K; Company On Track to Regain Fully Reporting Status
Marketwire Canada - Mon May 23, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 23, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company" , a diversified life sciences technology Company, today announced that it has both successfully completed the re-audit of its financial statements for the fiscal year ended March 31, 2014 and on May 20, 2016 filed its delinquent Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("2015 Form 10-K" .
Tauriga Sciences, Inc. Receives Notification From Federal Court That Its Trial Date Will Be January 23, 2017; Company Seeking Monetary Award(s) Exceeding $3,000,000 USD in Litigation Against Predecessor Audit Firm Cowan Gunteski & Co. P.A.
Marketwired - Wed May 11, 7:01AM CDT
NEW YORK, NY--(Marketwired - May 11, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company" , a diversified life sciences technology Company, today announced that it has been notified by the Federal Court (Southern District Florida) that the Company's Trial against its predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski" or "Cowan" , will take place on January 23, 2017 ("the Trial Date" or "the Trial" . The Trial will take place at 9:00 am EST in West Palm Beach Division ("Southern District Florida" before Judge Robin L. Rosenberg. Additionally the Pretrial Conference has been set for 9:30 am EST December 07, 2016 and the Calendar Call has been set for 9:00 am EST January 18, 2017.
Tauriga Sciences Inc. Retires $135,600 USD of Its Convertible Debt
Marketwire Canada - Fri May 06, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 6, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company" , a diversified life sciences technology Company, today announced it has repaid and retired $135,600 USD of its convertible debt. As of today's date, the Company has less than $225,000 USD of face value convertible debt remaining on its balance sheet. The Company will prioritize the strengthening of its balance sheet as it continues to negotiate with potential acquisition target(s).
Tauriga Sciences Inc. Completes $105,500 USD Equity Private Placement With Accredited Individual Investors
Marketwired - Mon Apr 18, 7:00AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company" , a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor. The terms of this private placement are as follows: $0.004 per share of common stock with a related three year warrant for 40% of each share of common stock purchased and an exercise price of $0.01 per share. The warrants require the investors to pay cash to exercise the warrants and do not allow for cashless exercise.
Tauriga Sciences Inc. Appoints Keith M. Berman PEO of Decision Diagnostics Corp. as a Member of its Board of Directors
ACCESSWIRE - Fri Apr 15, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company" , a diversified life sciences technology Company, today announced that it has appointed Mr. Keith M. Berman as a member of the Company's Board of Directors ("Board" . Mr. Berman will serve as an independent director and with this appointment, Tauriga's Board is now comprised of five members, four of which the Company believes qualify as independent directors under the regulations of the Securities and Exchange Commission. Currently, Mr. Berman serves as the Principal Executive Officer, Secretary and a member of the Board of Directors of Decision Diagnostics Corp. (OTC PINK: DECN) and he brings a wealth of experience in healthcare and life sciences fields.
Tauriga Sciences, Inc. to Proceed to Trial in its Ongoing Litigation Against its Predecessor Audit Firm Cowan Gunteski & Co. P.A.; Company to Seek Monetary Award(s) in Excess of $3,000,000 USD
ACCESSWIRE - Tue Mar 22, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company" , a diversified life sciences technology Company, has today announced that its good faith efforts to settle its ongoing litigation with Cowan Gunteski & Co. P.A. ("Cowan Gunteski" have proven unsuccessful. Therefore the Board of Directors ("the Board" of Tauriga has unanimously agreed to proceed to trial; the case is expected to proceed in Federal District Court -- Southern District Florida (Miami, Florida) with an expectation that the venue will be challenged. The lawsuit against Cowan Gunteski was initially filed by the Company on November 4, 2015 and subsequent to that there was a lengthy mediation process. The Company is continuing to seek the assistance of independent experts, to help ascribe dollar amounts for certain damages suffered by the Company ("provable damages" . At this point in time, the Company has realized out of pocket cash losses and debts (inclusive of liquidated damages) that exceed $850,000 USD. Additional potential damages include but are not limited to: inability to properly maintain Pilus Energy's Intellectual Property ("Pilus IP" , the July 31, 2015 delisting of TAUG shares from OTCQB to Pink Sheets, loss of market capitalization ("market cap" , loss of trading liquidity ("trading volume" , and loss of substantial business opportunities. In aggregate the Company intends to seek monetary award(s), during trial, in excess of $3,000,000 USD; that figure is expected to continually increase as additional time lapses. On a positive note, Cowan Gunteski has insurance coverage for its malpractice ("insurance coverage" .
Tauriga Sciences, Inc. Obtains its Audit Work Papers for Fiscal Years 2013 and 2014; Company Targeting the Summer of 2016 to Regain Fully Reporting Status
ACCESSWIRE - Tue Mar 08, 7:01AM CST
MIAMI, FL / ACCESSWIRE / March 8, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company" , a diversified life sciences technology Company, today announced that the Company has finally obtained its audit work papers for the fiscal years ended March 31, 2013 and 2014. Due to the PCAOB's public censure on July 23, 2015 of the Company's predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski" (http://pcaobus.org/Enforcement/Decisions/Documents/Cowan.pdf), the Company has been forced to re-audit its financial statements pertaining to Fiscal Year 2014 (ending March 31, 2014). The Company had been requesting these work papers from Cowan Gunteski since the middle of June 2015, coinciding with the engagement of its new independent registered public accounting firm. The Company's requests for its work papers were repeatedly ignored by Cowan Gunteski, but as the result of the recent mediation between the Company and Cowan Gunteski, these work papers were formally returned to the Company on Monday March 7, 2016.
Tauriga Sciences, Inc. Updates Shareholders on Status of Litigation and Efforts to Regain OTCQB Listing
ACCESSWIRE - Fri Feb 05, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, today provided shareholders with two important updates relating to its ongoing litigation with its predecessor audit firm Cowan Gunteski & Co. PA ("Cowan Gunteski" and its efforts to regain its status as a fully reporting OTCQB listed company. The Company is also actively evaluating potential acquisition candidate(s) in the life sciences space, should the Company be successful in its current initiatives.
Tauriga Sciences, Inc. Secures $180,000 USD in Non-Convertible Debt Financing From Singapore-Based Institutional Investor
Marketwired - Thu Oct 01, 10:45AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, has today announced the completion of $180,000 USD in Non-Convertible debt financing from Singapore-based institutional investor ALTERNATIVE STRATEGY PARTNERS PTE. LTD. ("ASP" . The debt carries a fixed interest rate per annum of 11.50% ("the Designated Rate" payable in full by December 23, 2015 ("the Maturity Date" . Both parties have discussed the possibility of amending terms, if necessary, under the assumption that both parties mutually agree to such amendment.
Tauriga Sciences Inc. Issues Shareholder Update on Status of Company and Future Strategic Plan
Marketwired - Fri Aug 14, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company, is providing its shareholders with a comprehensive update on the status of the Company as well as it strategic plan for the future. The Company's Board of Directors ("Board" has met multiple times over the past weeks to address several important issues. The Company will continually issue press releases to update shareholders whenever practicable.
Tauriga Sciences, Inc. Appoints Mr. Thomas J. Graham as a Member of the Board of Directors
Marketwired - Wed Aug 05, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company, today announced the appointment of Mr. Thomas J. Graham as the fourth member of the Company's Board of Directors ("Board" . The appointment is effective immediately and Mr. Graham will qualify as an "independent" under the rules of the Securities and Exchange Commission. In the future, Mr. Graham may also be appointed to certain committees of Board.
Tauriga Sciences Inc. Comments on the Status of Fiscal Year 2015 Form 10-K Filing
Marketwired - Fri Jul 31, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company, today commented about the status of its Form 10-K for the year ended March 31, 2015 (the "Form 10-K" .
Tauriga Sciences Inc. Granted 7 Day Extension by OTC Markets to Maintain Listing on OTCQB Exchange
Marketwired - Wed Jul 29, 3:50PM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company, today announced that is has been granted a 7 calendar day extension by OTC Markets to continue trading on the OTCQB exchange despite the Company's inability to file its Form 10-K for the year ended March 31, 2015 ("Form 10-K" with the Securities and Exchange Commission ("SEC" prior to 5:30 pm EDT today, July 29, 2015. If this extension had not been granted, Tauriga's common stock would have been moved to the OTC Pink Limited Information category at open of trading Thursday, July 30, 2015.
Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock
PR Newswire - Tue Jul 28, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company" , a diversified life sciences company, today announced that its stockholders approved an increase in the number of authorized shares of common stock of the Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting of Stockholders held on July 27, 2015 at the Law Offices of Nixon Peabody LLP in Midtown Manhattan (the "Special Meeting" . At the Special Meeting, there were 480,655,929 shares of common stock represented either by proxy or in person of the 929,825,933 shares of common stock entitled to vote, constituting a quorum. Of those shares, there were 433,331,977, or 90.2%, that voted in favor of the proposal recommended by the Board of Directors. The remaining votes were cast either against or as abstentions regarding the proposal.
Tauriga Sciences, Inc. to Complete the Increase of Authorized Shares Prior to Filing Fiscal Year 2015 Annual Report (Form 10K)
PR Newswire - Tue Jul 14, 2:03PM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company, today announced that the Company has decided to complete the proposed increase in authorized shares of common stock from 1 billion to 2.5 billion as more fully described in the Preliminary Schedule 14A filed with the Securities and Exchange Commission prior to filing its Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("Form 10-K" . The Company anticipates that it will be filing and mailing the Definitive Schedule 14A with the location and time of the special shareholder meeting. The Company will proceed to file its Form 10-K shortly thereafter and, if so, will not be at any risk of being delisted from the OTCQB exchange from the delay of filing Form 10-K.
Tauriga Sciences Inc. Announces Strategic Plan to Divest Natural Wellness Business
PR Newswire - Mon Jul 13, 7:01AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company" , a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it intends to fully divest its natural wellness business within the next two months. The Company has entered into a Letter of Intent to sell the assets of its natural wellness business. As part of the proposed transaction, Dr. Stella Sung would run the natural wellness business under its new corporate ownership, and Lawrence A. May, M.D. would serve as Chief Medical Officer. Accordingly, Dr. Sung has resigned her position as Tauriga's Chairman & CEO effective July 9, 2015 and Dr. May has resigned his position as Tauriga's Chief Medical Officer effective July 10, 2015. Dr. Sung will continue to support Tauriga in the important role of Chairman of the Medical Advisory Board.
Tauriga Sciences Inc. Issues Comprehensive Update to Shareholders and Reports Significant Progress on Multiple Fronts
Marketwire Canada - Wed Jun 01, 9:30AM CDT
NEW YORK, NY--(Marketwired - Jun 1, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today issued a comprehensive update to shareholders which addressed a number of important Corporate goals and milestones. The Company and its Board of Directors ("Board" strongly believe that important progress is being realized on multiple fronts. Tauriga Sciences Inc. Completes the Successful Re-Audit of Its Fiscal Year 2014 Financial Statements and Files Its Fiscal Year 2015 Form 10K; Company On Track to Regain Fully Reporting Status
Marketwire Canada - Mon May 23, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 23, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has both successfully completed the re-audit of its financial statements for the fiscal year ended March 31, 2014 and on May 20, 2016 filed its delinquent Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("2015 Form 10-K" . Tauriga Sciences, Inc. Receives Notification From Federal Court That Its Trial Date Will Be January 23, 2017; Company Seeking Monetary Award(s) Exceeding $3,000,000 USD in Litigation Against Predecessor Audit Firm Cowan Gunteski & Co. P.A.
Marketwired - Wed May 11, 7:01AM CDT
NEW YORK, NY--(Marketwired - May 11, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has been notified by the Federal Court (Southern District Florida) that the Company's Trial against its predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski" or "Cowan" , will take place on January 23, 2017 ("the Trial Date" or "the Trial" . The Trial will take place at 9:00 am EST in West Palm Beach Division ("Southern District Florida" before Judge Robin L. Rosenberg. Additionally the Pretrial Conference has been set for 9:30 am EST December 07, 2016 and the Calendar Call has been set for 9:00 am EST January 18, 2017. Tauriga Sciences Inc. Retires $135,600 USD of Its Convertible Debt
Marketwire Canada - Fri May 06, 7:00AM CDT
NEW YORK, NY--(Marketwired - May 6, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced it has repaid and retired $135,600 USD of its convertible debt. As of today's date, the Company has less than $225,000 USD of face value convertible debt remaining on its balance sheet. The Company will prioritize the strengthening of its balance sheet as it continues to negotiate with potential acquisition target(s). Tauriga Sciences Inc. Completes $105,500 USD Equity Private Placement With Accredited Individual Investors
Marketwired - Mon Apr 18, 7:00AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has completed an equity private placement for $105,500 USD to date comprised of accredited individual investors as well as one institutional investor. The terms of this private placement are as follows: $0.004 per share of common stock with a related three year warrant for 40% of each share of common stock purchased and an exercise price of $0.01 per share. The warrants require the investors to pay cash to exercise the warrants and do not allow for cashless exercise. Tauriga Sciences Inc. Appoints Keith M. Berman PEO of Decision Diagnostics Corp. as a Member of its Board of Directors
ACCESSWIRE - Fri Apr 15, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / April 15, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that it has appointed Mr. Keith M. Berman as a member of the Company's Board of Directors ("Board" . Mr. Berman will serve as an independent director and with this appointment, Tauriga's Board is now comprised of five members, four of which the Company believes qualify as independent directors under the regulations of the Securities and Exchange Commission. Currently, Mr. Berman serves as the Principal Executive Officer, Secretary and a member of the Board of Directors of Decision Diagnostics Corp. (OTC PINK: DECN) and he brings a wealth of experience in healthcare and life sciences fields. Tauriga Sciences, Inc. to Proceed to Trial in its Ongoing Litigation Against its Predecessor Audit Firm Cowan Gunteski & Co. P.A.; Company to Seek Monetary Award(s) in Excess of $3,000,000 USD
ACCESSWIRE - Tue Mar 22, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"
, a diversified life sciences technology Company, has today announced that its good faith efforts to settle its ongoing litigation with Cowan Gunteski & Co. P.A. ("Cowan Gunteski" have proven unsuccessful. Therefore the Board of Directors ("the Board" of Tauriga has unanimously agreed to proceed to trial; the case is expected to proceed in Federal District Court -- Southern District Florida (Miami, Florida) with an expectation that the venue will be challenged. The lawsuit against Cowan Gunteski was initially filed by the Company on November 4, 2015 and subsequent to that there was a lengthy mediation process. The Company is continuing to seek the assistance of independent experts, to help ascribe dollar amounts for certain damages suffered by the Company ("provable damages" . At this point in time, the Company has realized out of pocket cash losses and debts (inclusive of liquidated damages) that exceed $850,000 USD. Additional potential damages include but are not limited to: inability to properly maintain Pilus Energy's Intellectual Property ("Pilus IP" , the July 31, 2015 delisting of TAUG shares from OTCQB to Pink Sheets, loss of market capitalization ("market cap" , loss of trading liquidity ("trading volume" , and loss of substantial business opportunities. In aggregate the Company intends to seek monetary award(s), during trial, in excess of $3,000,000 USD; that figure is expected to continually increase as additional time lapses. On a positive note, Cowan Gunteski has insurance coverage for its malpractice ("insurance coverage" . Tauriga Sciences, Inc. Obtains its Audit Work Papers for Fiscal Years 2013 and 2014; Company Targeting the Summer of 2016 to Regain Fully Reporting Status
ACCESSWIRE - Tue Mar 08, 7:01AM CST
MIAMI, FL / ACCESSWIRE / March 8, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"
, a diversified life sciences technology Company, today announced that the Company has finally obtained its audit work papers for the fiscal years ended March 31, 2013 and 2014. Due to the PCAOB's public censure on July 23, 2015 of the Company's predecessor audit firm, Cowan Gunteski & Co. P.A. ("Cowan Gunteski" (http://pcaobus.org/Enforcement/Decisions/Documents/Cowan.pdf), the Company has been forced to re-audit its financial statements pertaining to Fiscal Year 2014 (ending March 31, 2014). The Company had been requesting these work papers from Cowan Gunteski since the middle of June 2015, coinciding with the engagement of its new independent registered public accounting firm. The Company's requests for its work papers were repeatedly ignored by Cowan Gunteski, but as the result of the recent mediation between the Company and Cowan Gunteski, these work papers were formally returned to the Company on Monday March 7, 2016. Tauriga Sciences, Inc. Updates Shareholders on Status of Litigation and Efforts to Regain OTCQB Listing
ACCESSWIRE - Fri Feb 05, 6:30AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2016 / Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, today provided shareholders with two important updates relating to its ongoing litigation with its predecessor audit firm Cowan Gunteski & Co. PA ("Cowan Gunteski" and its efforts to regain its status as a fully reporting OTCQB listed company. The Company is also actively evaluating potential acquisition candidate(s) in the life sciences space, should the Company be successful in its current initiatives. Tauriga Sciences, Inc. Secures $180,000 USD in Non-Convertible Debt Financing From Singapore-Based Institutional Investor
Marketwired - Thu Oct 01, 10:45AM CDT
Tauriga Sciences, Inc. (OTC PINK: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company focused on building its existing technologies and evaluating potential acquisition candidates, has today announced the completion of $180,000 USD in Non-Convertible debt financing from Singapore-based institutional investor ALTERNATIVE STRATEGY PARTNERS PTE. LTD. ("ASP" . The debt carries a fixed interest rate per annum of 11.50% ("the Designated Rate" payable in full by December 23, 2015 ("the Maturity Date" . Both parties have discussed the possibility of amending terms, if necessary, under the assumption that both parties mutually agree to such amendment. Tauriga Sciences Inc. Issues Shareholder Update on Status of Company and Future Strategic Plan
Marketwired - Fri Aug 14, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, is providing its shareholders with a comprehensive update on the status of the Company as well as it strategic plan for the future. The Company's Board of Directors ("Board" has met multiple times over the past weeks to address several important issues. The Company will continually issue press releases to update shareholders whenever practicable. Tauriga Sciences, Inc. Appoints Mr. Thomas J. Graham as a Member of the Board of Directors
Marketwired - Wed Aug 05, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today announced the appointment of Mr. Thomas J. Graham as the fourth member of the Company's Board of Directors ("Board" . The appointment is effective immediately and Mr. Graham will qualify as an "independent" under the rules of the Securities and Exchange Commission. In the future, Mr. Graham may also be appointed to certain committees of Board. Tauriga Sciences Inc. Comments on the Status of Fiscal Year 2015 Form 10-K Filing
Marketwired - Fri Jul 31, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today commented about the status of its Form 10-K for the year ended March 31, 2015 (the "Form 10-K" . Tauriga Sciences Inc. Granted 7 Day Extension by OTC Markets to Maintain Listing on OTCQB Exchange
Marketwired - Wed Jul 29, 3:50PM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today announced that is has been granted a 7 calendar day extension by OTC Markets to continue trading on the OTCQB exchange despite the Company's inability to file its Form 10-K for the year ended March 31, 2015 ("Form 10-K" with the Securities and Exchange Commission ("SEC" prior to 5:30 pm EDT today, July 29, 2015. If this extension had not been granted, Tauriga's common stock would have been moved to the OTC Pink Limited Information category at open of trading Thursday, July 30, 2015. Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock
PR Newswire - Tue Jul 28, 7:00AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or the "Company"
, a diversified life sciences company, today announced that its stockholders approved an increase in the number of authorized shares of common stock of the Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting of Stockholders held on July 27, 2015 at the Law Offices of Nixon Peabody LLP in Midtown Manhattan (the "Special Meeting" . At the Special Meeting, there were 480,655,929 shares of common stock represented either by proxy or in person of the 929,825,933 shares of common stock entitled to vote, constituting a quorum. Of those shares, there were 433,331,977, or 90.2%, that voted in favor of the proposal recommended by the Board of Directors. The remaining votes were cast either against or as abstentions regarding the proposal. Tauriga Sciences, Inc. to Complete the Increase of Authorized Shares Prior to Filing Fiscal Year 2015 Annual Report (Form 10K)
PR Newswire - Tue Jul 14, 2:03PM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company, today announced that the Company has decided to complete the proposed increase in authorized shares of common stock from 1 billion to 2.5 billion as more fully described in the Preliminary Schedule 14A filed with the Securities and Exchange Commission prior to filing its Annual Report on Form 10-K for the fiscal year ended March 31, 2015 ("Form 10-K" . The Company anticipates that it will be filing and mailing the Definitive Schedule 14A with the location and time of the special shareholder meeting. The Company will proceed to file its Form 10-K shortly thereafter and, if so, will not be at any risk of being delisted from the OTCQB exchange from the delay of filing Form 10-K. Tauriga Sciences Inc. Announces Strategic Plan to Divest Natural Wellness Business
PR Newswire - Mon Jul 13, 7:01AM CDT
Tauriga Sciences, Inc. (OTCQB: TAUG) or ("Tauriga" or "the Company"
, a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today announced that it intends to fully divest its natural wellness business within the next two months. The Company has entered into a Letter of Intent to sell the assets of its natural wellness business. As part of the proposed transaction, Dr. Stella Sung would run the natural wellness business under its new corporate ownership, and Lawrence A. May, M.D. would serve as Chief Medical Officer. Accordingly, Dr. Sung has resigned her position as Tauriga's Chairman & CEO effective July 9, 2015 and Dr. May has resigned his position as Tauriga's Chief Medical Officer effective July 10, 2015. Dr. Sung will continue to support Tauriga in the important role of Chairman of the Medical Advisory Board. 
